Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Crysvita Market Size And Revenue Forecast Through 2030
Growth during the historical timeframe was driven by a scarcity of therapies available for XLH, the granting of orphan drug designations, enhancements in diagnosing rare conditions, the uptake of treatment at specialized centers, and efforts from patient advocacy groups.
An increase in rare disease screening, a broader application of treatments for adult XLH, greater financial commitment to biologic orphan drugs, expanded reimbursement options, and enhanced long-term clinical results are driving the forecast period’s growth. Key developments shaping this period include the growing use of targeted therapies for uncommon conditions, the advancement of precision medicine in genetic illnesses, the widening availability of pediatric treatments for rare diseases, heightened public knowledge of X-linked hypophosphatemia, and a movement toward sustained disease management over time.
Download A Free Sample Report For Comprehensive Market Insights:
Crysvita Market Demand Drivers: What Is Fueling Industry Growth?
The growing trend of personalized medicine is set to boost the Crysvita market in the upcoming period. Personalized medicine refers to a medical practice that customizes treatment and healthcare strategies based on individual patient traits, including genetic composition, environment, and lifestyle, aiming for optimal and precise results. Progress in genomic technologies and an improved understanding of diseases facilitate the creation of targeted therapies tailored to unique genetic profiles. This synergy fuels the expansion of personalized medicine, enhancing therapeutic efficacy and patient outcomes. Crysvita serves as an example of personalized medicine by providing a focused therapy for X-linked hypophosphatemia (XLH), specifically catering to the distinct genetic and metabolic requirements of each patient to advance bone health and quality of life. For example, in February 2024, a report from the Personalized Medicine Coalition, a U.S.-based organization, indicated that the FDA approved 16 new personalized therapies for rare disease patients in 2023, increasing from six in 2022. These newly authorized personalized treatments for 2023 also comprise seven cancer medications and three for other ailments and conditions. Consequently, the rise of personalized medicine propels the Crysvita market.
Crysvita Market Segment Landscape: Which Areas Lead Market Development?
The crysvita market covered in this report is segmented –
1) By Type: 10 mg, 20 mg, 30 mg
2) By Patient Demographics: Pediatric, Adult
3) By Disease Prevalence: X-Linked Hypophosphatemia, Tumor-Induced Osteomalacia
4) By Application: Hospitals, Clinics, Other Applications
Crysvita Market Innovation Trends: Which Developments Are Transforming The Industry?
Leading players in the crysvita market are prioritizing the creation of more patient-friendly, prefilled delivery formats and enhancing treatment convenience to boost therapeutic access and improve health outcomes. For example, in June 2025, Kyowa Kirin Co Ltd., a pharmaceutical firm headquartered in Japan, secured approval for a new prefilled syringe version of Crysvita, providing a more convenient and safer choice compared to the traditional vial formulation. Initially authorized in 2019 and subsequently made available for home self-injection in 2020, Crysvita is used to address FGF23-related hypophosphatemic disorders, including XLH and TIO. This updated syringe design streamlines the administration process, cuts down on preparatory steps, and lessens the strain on patients, their families, as well as healthcare providers. As the sole treatment that directly targets FGF23, Crysvita® continues to be a vital option for managing phosphate regulation conditions. This product launch underscores Kyowa Kirin’s continuous dedication to advancing therapies that are more accommodating to patient needs.
Crysvita Market Industry Leaders And Market Competition
Major companies operating in the crysvita market are Kyowa Kirin Co. Ltd., Ultragenyx Pharmaceutical Inc.
Access The Complete Crysvita Market Report:
Crysvita Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the crysvita market in 2025. The regions covered in the crysvita market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model